In a sunlit lab in Newcastle upon Tyne, researchers at Northumbria University have quietly compiled a financial argument that could reshape British science: the UK’s non-animal testing sector is not just ethical—it’s booming. Between 2021 and 2024, the sector’s turnover surged from £947 million to over £1.2 billion, a growth spurt accompanied by a 13% annual rise in employment. This isn’t fringe science anymore—it’s a fast-moving economic force, and the numbers are too strong to ignore.
The study, led by Professor Elliott Johnson and his team at the Common Sense Policy Group, analyzed data from 75 UK companies working in Non-Animal New Approach Methodologies (NAMs). These are advanced tools like organ-on-a-chip systems and AI-driven toxicology models that are increasingly outperforming traditional animal tests. One standout, the Liver-Chip technology, correctly flagged 87% of drugs later found to harm human livers—far more accurate than animal trials, where about 90% of drugs that pass preclinical stages still fail in human trials.
But beyond the science, the economic case is now undeniable. The research, published in the NAM Journal, projects that if current trends hold, the sector could reach £2.12 billion in turnover and employ more than 12,000 people by 2030. Even more compelling: a £100 million public investment could generate £248 million in tax returns within seven years. Yet public funding remains starkly lopsided—just £2 million went to NAMs in 2019, compared to up to £1.1 billion for animal-based research.
The findings have already sparked debate in Parliament. Irene Campbell, chair of the All-Party Parliamentary Group on Phasing Out Animal Experiments in Medical Research, cited the study as the long-missing economic backbone for ethical reform. Meanwhile, international competitors are moving fast. The Netherlands has committed €245 million to animal-free biomedical research—more in one funding round than the UK has invested in over a decade.
The UK, the researchers argue, has all the ingredients to lead: world-class universities, a strong pharmaceutical industry, and independent regulatory capacity. But leadership requires investment. As Professor Howard Reed puts it, “Those advantages can be turned into global leadership”—if policymakers act. Lush Cosmetics, which commissioned the study through its Lush Prize, sees this as a moment of national opportunity. “This is a new frontier,” says director Karl Bygrave, “that the UK should be at the forefront of.”
The message is clear: the future of science is not only more humane—it’s more profitable. And the time to invest is now.